High expression of ANGPTL4 predicts adverse clinical outcomes in tumors, such as renal clear cell carcinoma, cholangiocarcinoma, melanoma, bladder cancer, and oral cancer [83–87]. Here, ANGPTL4 is linked to urinary bladder cancer.